SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing multi-specific, high-potency, human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders. The company utilizes a proprietary platform based on advanced genetic engineering and antibody science to produce hIgG using transchromosomic cattle, known as Tc-Bovine, without the need for human plasma donors. Its lead product candidate, SAB-142, is a multi-specific, fully human anti-thymocyte globulin (hATG) in clinical development for the treatment of autoimmune type 1 diabetes (T1D), aiming to delay disease onset and prevent progression in Stage 3 patients. SAB-142 is currently undergoing a registrational Phase 2b clinical trial named SAFEGUARD, which targets newly diagnosed adult, adolescent, and pediatric T1D patients. The company has established regulatory pathways with the U.S. Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Therapeutic Goods Administration (TGA) in Australia. Founded in 2014, the company has conducted multiple clinical trials to build a safety and immunogenicity database for its antibody platform.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage sab.bio
Sector Healthcare IR page ir.sab.bio
Tags
autoimmune diseases, type 1 diabetes, immunoglobulin g, anti-thymocyte globulin, transchromosomic cattle, disease-modifying therapy, clinical-stage biopharmaceuticals, polyclonal antibodies, SAB-142, Tc-Bovine, SAFEGUARD, HUMAN Trial
Press page —

Metrics

Valuation  
Market cap $ 288.908M
Market cap (USD) $ 288.908M
P/E -2.38
PEG —
P/BV 1.37
P/S 218.47
P/OCF -5.36
P/FCF -6.32
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.0%
ROI 9.2%
ROIC -25.5%
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -26.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 0 1.322M 2.239M 23.904M 60.876M 55.238M
Net profit 13.274M -34.105M -42.194M -18.741M -17.145M 20.118M
Free cash flow -45.708M -34.629M -25.317M -25.626M -7.185M -2.727M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.74 3.79 0.69 0.59 7.81 —
Price performance 12m -0.01 4.52 0.17 -0.92 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 8.01M 5.56M 0.00 — —
↳ YoY growth -30.6% -100.0%
Lease liabilities (USD) 7.42M 6.72M 4.61M 4.86M 4.39M 5.95M
Cash and deposits (USD) 12.6M 33.2M 15M 56.6M 8.9M 10.5M
Right-of-use assets (USD) 3.05M 2.62M 1.19M 1.28M 970,294 2.6M
Cash flow detail
Operating cash flow (USD) 10M 3.76M -23.5M -25.1M -34.3M -44.8M
Purchases of property, plant and equipment (USD) -12.7M -10.9M -2.17M -197,154 -337,262 -933,156
Change in receivables (cash effect) (USD) -17.8M 12.6M 2.45M 5.56M — —
Change in payables (cash effect) (USD) 5.21M -2.94M -779,425 -2.7M 923,323 1.48M
Interest paid (cash effect) (USD) -469,151 -294,459 -293,392 -245,481 -373,954 -242,032
Income taxes paid (cash effect) (USD) — 0.00 -25,629 — — —
Share-based compensation (USD) 1.3M 2.31M 2.67M 2.42M 2.94M 5.21M
Operating cash flow before change in receivables (USD) 27.8M -8.8M -25.9M -30.7M — —
Free cash flow (OCF - PPE - intangibles) (USD) -2.73M -7.19M -25.6M -25.3M -34.6M -45.7M
Income detail
Research and development expense (USD) 27.9M 57.2M 36.4M 16.5M 30.3M 34.4M
↳ 5y CAGR +4.2%
Total comprehensive income (USD) — — -18.7M -42.2M -34.3M 13.6M
Comprehensive income to owners (USD) — — -18.7M -42.2M -34.3M 13.6M
Reported Mar 29, 2022 Apr 14, 2023 Mar 29, 2024 Mar 29, 2024 Mar 31, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 29, 2026

PDF Version

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.

To access the live conference call, participants may register here.

Conference Details:

Conference Date: Thursday, November 5, 2026 Conference Time: 08:30 AM ET U.S. Dial-in: 1-877-704-4453 International Dial-in: 1-201-389-0920 Conference ID: 13762793 Conference Call Name: SAB BIO Q3 2026 Earnings Call

Following the conference call, a replay of the audio webcast will be available under the Investors & Media section of the Company’s website at www.sab.bio.

About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is being evaluated in two clinical trials: the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE-hATG study for people up to two years following a Stage 3 T1D diagnosis. For more information, visit www.sab.bio.

Oct 14, 2026

PDF Version

MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference:

Date: October 20, 2026 Time: 11:15 - 11:30 a.m. ET Format: Fireside Chat Presenter: Samuel J. Reich, Chief Executive Officer Location: New York, NY Webcast: Register here

SAB BIO management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. To access replay webcasts of investor events, please visit the Investors & Media section of SAB BIO’s website at www.sab.bio.

About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

Oct 13, 2026

PDF Version

Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes

MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new-onset Stage 3 T1D.

Fast Track designation is intended to facilitate the development and expedite the review of therapies for serious conditions where there is an unmet medical need and to help bring important new treatments to patients earlier.

“Receiving FDA Fast Track designation is an important regulatory milestone for SAB-142 and reflects the agency’s determination that the program has the potential to address an unmet medical need for people diagnosed with type 1 diabetes,” said Samuel J. Reich, Chief Executive Officer of SAB BIO. “We look forward to continuing to work closely with the FDA as we advance the SAB-142 clinical program. This designation represents meaningful progress toward our goal of bringing SAB-142 to people living with type 1 diabetes as quickly as possible and transforming the meaning of a T1D diagnosis.”

SAB-142 is currently being evaluated in the registrational Phase 2b SAFEGUARD study in people within 100 days of a Stage 3 T1D diagnosis, with enrollment expected to be completed in Q4 2026 and topline data anticipated in 2H 2027. The program is further supported by the investigator-led Phase 3 PRISE-hATG study, which is designed to evaluate SAB-142 in people with Stage 3 type 1 diabetes from 100 days to two years following diagnosis.

About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

Forward-Looking Statements Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the FDA Fast Track designation and potential expedited development for SAB-142 to address an area of serious unmet need in Stage 3 T1D; the therapeutic potential of SAB-142 to be a treatment for T1D, the expectations regarding timing for enrollment and topline data, and the overall development of SAB BIO’s T1D program.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Prompts

SAB Biotherapeutics, Inc. (ticker SABS), listed in United States.

Company History

Date Change Detail
Oct 26, 2021 Renamed BIG CYPRESS ACQUISITION CORP. → SAB BIOTHERAPEUTICS, INC.
— Former tickers SABSW

ETFs Holding SAB Biotherapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.45% 104,849 $ 309.305K Nov 17, 2026
AVSC 0.01% 122,435 $ 367.305K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
SABS canonical Common share — US nasdaq 3.17 USD 2026-09-30
SABSW Warrant — US nasdaq 0.01 USD 2026-09-30